GeneGoCell Inc.’s Post

#Genetherapy platforming: optimizing #TFF for downstream #AAVprocessing For #viralvector-based gene therapies, TFF roles are still being established as the platform is in its early stages. This month, join Cytiva’s Luke McCarney (Filtration Engineer) as he compares different TFF technologies for #AAVdownstreamprocessing based on format (hollow fiber and flat sheet) and membrane chemistry. He will also present data from common #AAVserotypes at various downstream steps, comparing key performance metrics such as flux, purity, and yield. Register for this #webinar below:

#Genetherapy platforming: optimizing #TFF for downstream #AAVprocessing For #viralvector-based gene therapies, TFF roles are still being established as the platform is in its early stages. Next month, join Cytiva’s Luke McCarney (Filtration Engineer) as he compares different TFF technologies for #AAVdownstreamprocessing based on format (hollow fiber and flat sheet) and membrane chemistry. He will also present data from common #AAVserotypes at various downstream steps, comparing key performance metrics such as flux, purity, and yield. Register for this #webinar below:

One week to go until the experts in market access, regulatory affairs, and non-clinical strategy at the Cell and Gene Therapy Catapult will be delivering a webinar on 'Developing a robust target product profile (TPP) for successful therapy adoption'. If you are looking to improve your understanding of the characteristics of a TPP, attending this webinar is essential to learn how to create your own robust #TPP and increase the likelihood of successful adoption of your #AdvancedTherapy. Learn more: https://buff.ly/3RqT2nC ##TPP #CGTDeveloper #CellTherapies #GeneTherapies

Good framework for comparability, thanks Kumud Raj Poudel et al for laying this foundation as many cell and gene programs advance to later stage development and commercialization!

See you in Rome next week at #ESGCT2024 ! 🍕 ❓ Are you encountering challenges with your Cell & Gene Therapy clinical trials ? Or perhaps you're planning one and would like to better understand the challenges and how to navigate them? Let’s connect and discuss how we can help you succeed! 🤝 📩 Feel free to drop me a message, and we can schedule a time to chat. Looking forward to fruitful conversations and insights ! #Biotech #Pharma #CellTherapy #GeneTherapy

Are you a drug developer and want to know how to increase the likelihood of successful clinical adoption of your advanced therapy? Register at the link below and hear from my colleagues at the Non-clinical, Regulatory Affairs, and HEMA teams at Cell and Gene Therapy Catapult to improve your understanding of the target product profile (TPP) for a more effective translation of your product. #clinicaladoption #catapult #CGTC #nonclinical #HEMA #regulatoryaffairs #TPP

Interested in learning how the #AdvancedTherapies industry can enhance today's manufacturing practices to establish fully automated, digitally integrated processes? ➡️ https://buff.ly/3BthKPL Daniel Gibson, Head of Collaborations at the Cell and Gene Therapy Catapult, highlights this and more in his key takeaways from Phacilitate's recent Advanced Therapies Europe event. Read the blog ☝️ #CellTherapy #GeneTherapy #ATMPs

Day 2 of the Keystone Symposia Targeting Dry Age-Related Macular Degeneration: Pathophysiology and Emerging Therapies conference. Meet with or DM the Entos Pharmaceuticals team, Jason Ding, FCPA, FCA, Ping Wee, and Jailal Ablack attending the conference. Don't miss this poster! Poster Session 2, September 19, 7:30 to 9 pm Presenter: Ping Wee Title: Optimizing Ocular Gene Therapy: Harnessing the Potential of the Proteolipid Vehicle Nucleic Acid Delivery Platform #Fusogenix #PLV #genetherapy #ocular

Over the next two weeks, we would like to reintroduce you to the great content our members have created to address the various challenges around validation within ATMPs.    You can download our validation challenges paper here: https://lnkd.in/e73dpJd8    Or watch the webinar summarising the paper’s content here: https://lnkd.in/eg5NMYSK    Within this paper, members of BioPhorum Advanced Therapy Medicinal Products highlight the complexity and challenges associated with validating cell and gene therapy products, as well as sharing potential options to help resolve them.    Some of the challenges showcased in the paper include having a limited number of batches available at commercial scale prior to and during PPQ, assay variability, and reference standards.    Having greater awareness of possible issues and addressing them as early as possible will help provide a clear and fast path for successful validation of process and analytical methods. We therefore hope you will find these resources of value.    For further information on BioPhorum Advanced Therapy Medicinal Products’ publications visit:    https://lnkd.in/exqf9Khu    #ATMP #celltherapy #genetherapy #validation